BRCA1 gene mutations may not be key to prostate cancer initiation, as previously thought

May be time to reassess use of PARP inhibitor drugs in these patients, say researchers Findings pave way for refining genetic testing and personalised treatment in prostate cancer Mutations in the BRCA1 gene that are either inherited (germline) or acquired (somatic) might not be key to the initiation of prostate ...

2025-02-25T17:36:11+00:0025 February 2025|BMJ Oncology, Press release|
Go to Top